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patients had received chemotherapy, 18% had undergone surgery and 
50% had received radiation therapy. Still in this group of patients (lung 
cancer) performance Status (PS) was 0 or 1 in 29% of patients, 2 in 
14%, 3 or 4 in 15% (missing data: 42%).
Overall, 39% of patients were malnourished. For all patients included 
in the study, the prevalence of malnutrition was 14.4%, 31.4%, 52.3%, 
53.6%, and 65.3% in patients with a PS ranging from 0 to 4, respec-
tively. Prevalence of malnutrition in lung cancer patients was 45%: 5% 
of patients with localized cancer, 22% with loco-regional cancer and 
73% with metastatic cancer. 
Regarding the nutritional support in the overall population of patients, 
57.6% of malnourished patients versus 28.4% of well nourished 
patients had at least one of the following nutritional supports: dietetic 
advices, oral supplementation, enteral nutrition and/or parenteral nutri-
tion. Among all lung cancer patients (N = 247), 42.9% had nutritional 
support: 38.8% received oral supplementation, 11.1% had enteral nutri-
tion and 8.1% had parenteral nutrition.
Conclusions: Along with an improvement of cancer treatments, the 
prevalence of malnutrition is still very high in lung cancer patients. 
Systematic screening and care of malnutrition are mandatory in these 
patients. 
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Aims: To evaluate the prevalence of anaemia (haemoglobin [Hb] <12.0 
g/dL) among hospitalised cancer patients (long term and day hospital) 
in France.
Material and Methods: A written invitation to participate in a one 
day survey of anaemia among hospitalised French cancer patients on 
November 14, 2006, was sent to all practising hospital-based French 
oncologists, haematologists and pulmonary specialists (n=4165). 255 
physicians provided data. Age, gender, cancer type and treatment, 
Hb value, type of anaemia and treatment for anaemia were recorded. 
Unless otherwise speciﬁed, data are presented as mean ± standard 
deviation.
Results: 4,161 patients (mean age, 62.2±14.6 years; males, 53.2%) 
from 255 physicians were described. The patients were admitted for 
chemotherapy (CT) (57.6%), initial staging and follow-up (19.6%), 
radiotherapy (5.2%), supportive care (22.6%), and/or other (20.6%). 
57.8% of patients had a hospital stay >24 hours. 76.9% of patients 
received cancer treatment (recurrent disease: 44.2%); 42.7% of patients 
had a performance status of ≥2. 23.8% of patients had haematological 
malignancies (including lymphoma, 8.9%; and acute leukaemia, 6.3%) 
and 76.2% had solid tumours (including lung cancer 15.9%; colorectal 
cancer 14.4%; and breast cancer 12.8%). 57.6% of solid tumours were 
metastatic. Hb levels ranged from a minimum of 4.2 to a maximum of 
18.9 g/dL (11.2±1.9). 63.8% of patients had anaemia (77.3% among 
patients with haematological tumours; 59.5% in patients with solid 
tumours). 57.8% of anaemia cases were considered to be related to 
cancer treatment. 59.1% of patients receiving CT were anaemic. 47.4% 
of anaemic patients were not being treated for their anaemia. Among 
patients receiving 1 or more treatment for anaemia, the treatments in-
cluded transfusion (28.5%), erythropoiesis-stimulating protein (27.0%), 
and nutritional supplements (iron and/or vitamins) (19.1%). Further 
analysis of patients not treated for anaemia is underway. 
Conclusions: The high prevalence of anaemia among cancer patients 
in our survey is consistent with ﬁndings of ECAS, which found a 
prevalence of anaemia in 67% of patients in a large European survey of 
anaemia in this setting. Better identiﬁcation of the causes of anaemia in 
cancer patients may optimise patient care. Detailed data on lung cancer 
patients will be presented.
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Background: Brain tumors cause threats to wellbeing for patients, and 
pose unique challenges in care provision by family members. Lung 
cancer patients are prone to developing intracranial metastases. Primary 
and metastatic brain tumors and their treatments may engender physical 
and psychological disorders, including fatigue, cognitive impairment, 
and changes in patients’ insight and judgment. There is a lack of infor-
mation about the relationship between these problems and the inﬂu-
ence of patient variables such as age, gender, economic status, stage of 
disease and treatment, medications, and co morbid conditions. 
Appraisal and reporting of symptoms by these patients may be difﬁcult 
for them, often resulting in ‘proxy’ symptom assessment by the primary 
care provider. There is debate about the congruency of these two per-
spectives and how it might impact health-seeking behaviors, including 
accessing support for symptom management from professional care 
providers. 
The Edmonton Symptom Assessment Scale (ESAS) was used by our 
cancer centre for two days in 2006 to document symptom severity 
in all cancer patients and found that lung and brain cancer patients 
ranked tiredness and impaired general wellbeing as their most severe 
symptoms. In addition, data from a 2006 British Columbia Ministry of 
Health province wide ambulatory oncology survey found that patients 
reported gaps in their care ranging from education and communication 
to emotional support required to alleviate fears and anxieties. 
Purpose of the Study and Methods: This study will document the 
perception of symptom intensity in patients with primary brain cancer, 
in patients with metastatic brain lesions from lung cancer, and from 
the perspective of their caregivers. We will use the ESAS to assess 
the perception of symptom severity in 50 lung cancer patients with 
brain metastases and 50 primary brain tumor patients. An independent 
assessment of the perception of symptom severity for each patient 
will be completed by a family caregiver. A cognitive assessment using 
the Montreal Cognitive Assessment (MOCA) of patients will clarify 
whether symptoms are associated with cognitive impairment. Other 
important patient variables will be documented. Finally, an assessment 
of caregivers’ sense of competency will guide the development of an 
intervention to assist them in care provision. 
By analyzing the symptom assessment and questionnaire data provided 
by the patients and their primary caregiver we will develop a support-
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ive intervention to meet the needs of these patient populations and their 
caregivers. 
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Background: The assessment of performance status according to the 
classical Karnofsky or ECOG scales has been shown to be an effec-
tive predictor of outcome in several oncological studies. However, its 
application to patients over 70 years of age has limited utility and may 
uderrepresent the degree of functional impairment). Comorbidity and 
functional status according to ECOG, ADL and IADL have shown 
to be independent in older cancer patients. However, some degree of 
correlation between comorbidity and IADL has been reported before. 
Geriatric assessment is a time-consuming task sometimes difﬁcult to 
perform by oncologists out of clinical trials. The experience of a single 
institution about elderly lung cancer patients in an out patient setting 
will be presented. 
Methods: For geriatric assessment the following characteristics were 
considered:
• Comorbidity by means of Charlson and Kaplan Feinstein scores
• Activities of daily living (ADL)
• Instrumental activities of daily living (IADL)
• Nutritional status by means of proteins/albumin levels and/or BMI
• Cognitive mental status is examined with the Mini-Mental state
• Expression of depression with the Geriatric Depression Screening
• Scale (GDSS)
• Family/Institutional support.
Results: By Febrery/2007 seventy elderly lung cancer patients (pts) 
have been analyzed in our institution. The main descriptive character-
istics were: median age 76 years (70-84 ); stage disease, II in 5.7 %, III 
in 45.8 % and IV in 57.1 % of the pts; distribution of performance sta-
tus (ECOG) was: PS 0/10 %, PS 1/50 % and PS 2/40 %; sex: M (84 %) 
and F (16 %). Serum albumin level was lesser than 3.5 g/dl in 28 % of 
the patients. Comorbidity according to Charlson and Kaplan scales was 
presented in 74.2 % and 82 % of pts respectively. Ability in 51-99 % of 
ADL and IADL was able in 25 % and 39.7% of pts and was < 50 % in 
8.8 % and 22.1 % of pts. Mini-Mental state was applied to 33 patients, 
40 % of them obtained a punctuation < 25. Treatment administered was: 
surgery in 1 pt, radiotherapy alone in 2 pts, chemo-radiotherapy in 11 
pts, chemotherapy alone in 55 pts and tyrosine-kinase inhibitor in 1 pt.
Conclusions: The analysis is ongoing but the heterogeneity of the 
pts in these preliminary results suggests the importance to carry out a 
detailed evaluation of elderly lung cancer patients for detecting several 
situations not detectable by means of a conventional examination. A 
more completed analysis of comorbid, clinical, nutritional and social 
conditions will be presented at the meeting. Correlation between dif-
ferent factors and the inﬂuence of them on the outcome of the elderly 
patients will be examined. 
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Background: As there are few published data on the treatment costs 
of lung cancer, health economic data is valuable for physicians making 
treatment decisions as well as health authorities to develop reimburse-
ment and treatment guidelines. This study is aimed to collect data on 
direct health care costs related to treatment of advanced stage IIIB/IV 
non-small cell lung cancer (NSCLC) in Finland. 
Methods: The costs analysis was based on data reﬂecting consumption 
of the health care resources and medication in Helsinki University Hos-
pital and Turku University Hospital. The data was collected retrospec-
tively from the medical records of 65 advanced stage IIIB/IV NSCLC 
patients who participated in a phase IV erlotinib clinical trial (TRUST). 
In this abstract, interim data on 42 patients is presented. The resource 
utilization data for all treatments was collected from the day patients 
ﬁrst visited the health care unit with diagnosed advanced stage IIIB/IV 
NSCLC until discontinuation of therapy or patient death. The following 
cost categories were included in the analysis: total direct health care 
costs, chemotherapy costs (including drug and administration costs) 
and costs associated with adverse reactions. The 2001 Finnish Guide-
lines for Health Care Unit Costs converted to 2005 cost levels were 
used to value the costs of the health care resources. A published price 
list of pharmaceuticals (SLD Price 2006) was used to value the prices 
of chemotherapies and other medications.
Results: In the interim analysis, the mean total costs per patient in 
different treatment lines were; Line 1 (n=37): 10 652 €; Line 2 (n=35): 
10 054 €; Line 3 (n=26): 10 143 €; Line 4 (n=6): 12 790 €. The mean 
total costs per patient in different chemotherapies were; combination 
treatments (n=34): 11 359 €; docetaxel (n=7): 15 933 €; vinorelbine 
(n=5): 13 819 €; gemcitabine (n=2): 6 184 €; pemetrexed (n=8): 12 
618 €; erlotinib (n=42): 8 407 €; other (n=6): 8 871 €. The mean costs 
of adverse reactions per patient (out-patient visits or hospital days) 
were; erlotinib (n=14): 130 €; other chemotherapy (n=13): 1 796 €.
Conclusions: The total average cost per advanced stages IIIB/IV 
NSCLC patient was 30 900 €. The major cost drivers in all treatment 
lines were chemotherapy (including drug and administration costs) and 
hospitalization costs. In treatment of advanced stage IIIB/IV NSCLC, 
treatment with erlotinib incurred the lowest treatment costs (including 
drug and administration costs) and AE related costs. Final results of the 
analysis will be presented in the conference.
